VANGUARD GROUP INC 13D and 13G filings for Apellis Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-13 4:58 pm Purchase | 2023-12-29 | 13G | Apellis Pharmaceuticals, Inc. APLS | VANGUARD GROUP INC | 9,555,678 8.060% | 343,187 (+3.73%) | Filing |
| 2023-02-09 11:07 am Purchase | 2022-12-30 | 13G | Apellis Pharmaceuticals, Inc. APLS | VANGUARD GROUP INC | 9,212,491 8.330% | 1,295,392 (+16.36%) | Filing |
| 2022-02-09 3:24 pm Purchase | 2021-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS | VANGUARD GROUP INC | 7,917,099 8.140% | 2,375,274 (+42.86%) | Filing |
| 2021-02-10 10:30 am Purchase | 2020-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS | VANGUARD GROUP INC | 5,541,825 7.320% | 5,541,825 (New Position) | Filing |